Docket #: S21-137

Metabolic Subphenotype Predictor – software for continuous glucose monitoring

Stanford researchers at the Snyder Lab have developed a novel software application, called the Metabolic Subphenotype Predictor, which predicts if a patient is insulin resistant through continuous glucose monitoring.

Current methods of identifying pre-diabetes are blood tests that predict insulin resistance, but do not identify other metabolic subphenotypes. Additionally, these tests are not readily available to the general public. This method defines the dominant metabolic phenotype using the shape of a glucose curve after administering an oral glucose tolerance test. This invention makes testing for diabetes more accessible and cost effective, while providing personalized medical treatment and targeted lifestyle interventions.

Stage of Development
Research -

in vivo

Related Technology
[Stanford Docket S18-198-Continuous glucose monitoring classification algorithm to identify glucotypes at diabetes risk](#)

Applications

- Companion software for continuous glucose monitoring devices

Advantages

- **Novel software application** that is not available anywhere else
- **Accessible diagnosis** for rural and underserved areas
- **Personalization of medical treatment and targeted lifestyle interventions** based on the identification of the dominant metabolic phenotype

Patents

- Published Application: [20220406400](#)

Innovators

- Tracey McLaughlin
- Michael Snyder
- Ahmed Metawally
- Dalia Perelman

Licensing Contact

Hyunjin Kim

Licensing Manager, Life Sciences

[Email](#)